Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

Full Story →